繁體版 / 簡體版
 
R&D PORTFOLIO
/ ON101

ON101

Indication
Diabetic foot ulcer (DFU)
Product Advantages
1.Anti-inflammation
2.Enhanced the skin cells migration and proliferation
3.Enhanced collagen synthesis
4.Tissue remodeling
Status
1.Taiwan new drug certificate is currently under reviewing.
2.Executing the phase III clinical trials in the China and the United States.
Product Advantages
1.Efficacy: Clinical studies demonstrated that ON101 has significant therapeutic effects on wound healing and could reduce scar formation.
2.Cost advantage: Integration of new drug research and development, botanical planting, and drug product manufacturing to control costs. Exclusive share of the global DFU market.
Potential Market
Diabetic Foot Ulcer market is in value from $292.1 Million in 2015 to $873.4 Million by 2025, representing a compound annual growth rate of 11.6%.

  • The new drug ON101 for diabetic foot ulcer has reached the goal after interim analysis in phase III clinical trial in Taiwan. The complete wound healing rate is over 60% after 16 weeks treatment. The clinical efficacy of ON101 is better than the current drug Regranex. It will be the first natural source of therapeutic drugs for DFU with the greatest value in the market.
  • The patents of ON101 plant extracts, uses and process technologies have been completed with a global patent layout to protect the intellectual property and technology. The patents granted countries including the Republic of China, the United States, the European Union, Malaysia, India, Japan, China, South Korea and Russia.


陕西快乐十分中奖技巧 广东26选5好彩2 精准一头一尾中特免费网站期期准 (★^O^★)MG亚洲幻想_稳赢版 河北快3开奖号 (*^▽^*)MG对决沙龙爆分打法 西欧娱乐 欢乐生肖要用久停售了吗 (^ω^)MG富豪生活_豪华版 (^ω^)MG太阳神之忒伊亚送彩金 (★^O^★)MG三个朋友如何爆大奖 福彩黑龙江36选7 (^ω^)MG财炮连连试玩网站 神州彩票网 (*^▽^*)MG诙谐财富APP下载 福彩湖北30选5开奖结果查询 (^ω^)MG经典老虎机试玩网站